AIM ImmunoTech Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.0M
- Price
- $0.288
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.69%
- Volume
- 661.8K
Quote data as of 5:20 AM ET
About
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Quick stats
Shares outstanding27.7M
Computed float7.8M
Float sourceUnknown
Cash runway (months)2.1
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000946644
Websitehttps://aimimmuno.com
AI Summary
AI-generated2d agostandardbullishoperations updateAIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech released a new CEO Corner segment featuring Thomas Equels discussing the successful completion of patient enrollment and dosing in the DURIPANC Phase 2 clinical program for pancreatic cancer.
The segment highlights encouraging interim clinical observations and favorable safety findings for Ampligen in combination with AstraZeneca's Imfinzi, alongside ongoing Phase 3 planning activities.
Management characterized the current period as one of the most catalyst-rich in the company's history, citing progress in its strategic collaboration and IP expansion targeting immunologically "cold" tumors.